Bryostatin Activates CAR T-Cell Antigen-Non-Specific Killing (CTAK), and CAR-T NK-Like Killing for Pre-B ALL, While Blocking Cytolysis of a Burkitt Lymphoma Cell Line

The advent of CAR-T cell therapy has changed the face of clinical care for relapsed and refractory pre-B-acute lymphocytic leukemia (B-ALL) and lymphoma. Although curative responses are reported, long-term cures remain below 50%. Different CAR T-cell leukemia targets appear to have different mechani...

Повний опис

Бібліографічні деталі

Автори:	Lingyan Wang, Yue Zhang, Eden Anderson, Adam Lamble, Rimas J. Orentas
Формат:	Artigo
Мова:	Inglês
Опубліковано:	Frontiers Media S.A. 2022-02-01
Серія:	Frontiers in Immunology
Предмети:	CAR-T cell CD22 adoptive immunotherapy antigen density innate immunity T cell
Онлайн доступ:	https://www.frontiersin.org/articles/10.3389/fimmu.2022.825364/full
Теги:	Додати тег Немає тегів, Будьте першим, хто поставить тег для цього запису!